STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience (TWST) CEO sells shares under preset plan

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust sold a total of 41,570 shares of common stock on August 25, 2026 in multiple open-market transactions under a previously adopted Rule 10b5-1 trading plan. The reported weighted average sale prices ranged from about $150.56 to $154.45 per share across the trades. Leproust also continues to hold several employee stock option positions, including performance stock options exercisable into 64,950 shares of common stock at an exercise price of $67.85 per share expiring on August 31, 2030.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Leproust Emily M.
Role Chief Executive Officer
Sold 41,570 shs ($6.32M)
Type Security Shares Price Value
Sale Common Stock F1, F2 12,648 $150.564 $1.90M
Sale Common Stock F1, F3 12,236 $151.355 $1.85M
Sale Common Stock F1, F4 6,412 $152.75 $979K
Sale Common Stock F1, F5 9,181 $153.927 $1.41M
Sale Common Stock F1, F6 1,093 $154.446 $169K
holding Employee Stock Option (right to buy) F7 -- -- --
holding Employee Stock Option (right to buy) F8 -- -- --
holding Employee Stock Option (right to buy) F9 -- -- --
holding Employee Stock Option (right to buy) F10 -- -- --
holding Employee Stock Option (right to buy) F11 -- -- --
Holdings After Transaction: Common Stock — 770,729 shares (Direct); Employee Stock Option (right to buy) — 64,950 shares (Direct)
Footnotes (11)
  1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $150.00 to $150.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $151.00 to $151.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $152.33 to $153.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  5. F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $153.34 to $154.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  6. F6. Represents the weighted average sales price per share. The shares sold at prices ranging from $154.34 to $154.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  7. F7. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  8. F8. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  9. F9. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  10. F10. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  11. F11. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Shares sold 41,570 shares Total common shares sold by CEO on August 25, 2026
Sale price (weighted average 1) $150.564 per share Weighted average price for 12,648-share sale on August 25, 2026
Sale price (weighted average 2) $151.355 per share Weighted average price for 12,236-share sale on August 25, 2026
Sale price (weighted average 3) $152.750 per share Weighted average price for 6,412-share sale on August 25, 2026
Sale price (weighted average 4) $153.927 per share Weighted average price for 9,181-share sale on August 25, 2026
Sale price (weighted average 5) $154.446 per share Weighted average price for 1,093-share sale on August 25, 2026
Performance stock option exercise price $67.85 per share Performance options on 64,950 underlying TWST shares expiring August 31, 2030
Underlying shares for performance stock options 64,950 shares Common stock underlying performance stock options exercisable at $67.85
Rule 10b5-1 trading plan regulatory
"The transactions reported ... were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price per share financial
"Represents the weighted average sales price per share."
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)""
performance stock options financial
"Represents performance stock options granted to the reporting person"

FAQ

What insider transaction did TWST report for CEO Emily Leproust on this Form 4?
The filing reports that CEO Emily M. Leproust sold 41,570 shares of Twist Bioscience common stock on August 25, 2026 in multiple open-market transactions, as reflected in five separate sale entries on the Form 4.

At what prices did the TWST CEO sell shares on August 25, 2026?
The CEO’s sales used weighted average prices of $150.56, $151.36, $152.75, $153.93, and $154.45 per share, with footnotes stating that individual trades occurred in price ranges from $150.00 up to $154.64 per share.

Was the TWST CEO’s August 25, 2026 stock sale under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan previously adopted by Emily M. Leproust on May 27, 2025, indicating the trades were pre-arranged pursuant to that plan.

How many TWST shares did the CEO sell in total according to this Form 4?
According to the transaction summary, Emily M. Leproust sold a total of 41,570 shares of Twist Bioscience common stock across five open-market sale transactions reported for August 25, 2026.

What stock options for TWST does the CEO still hold per this filing?
The filing lists several employee stock options, including performance stock options with an exercise price of $67.85 per share, expiring on August 31, 2030, covering 64,950 underlying shares of Twist Bioscience common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leproust Emily M.
(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/25/2026S(1)12,648(2)D$150.564799,651D
Common Stock08/25/2026S(1)12,236(3)D$151.355787,415D
Common Stock08/25/2026S(1)6,412(4)D$152.75781,003D
Common Stock08/25/2026S(1)9,181(5)D$153.927771,822D
Common Stock08/25/2026S(1)1,093(6)D$154.446770,729D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$5.95 (7)09/28/2025Common Stock00D
Employee Stock Option (right to buy)$8.82 (8)09/28/2027Common Stock075,439D
Employee Stock Option (right to buy)$26.66 (9)11/18/2028Common Stock0133,269D
Employee Stock Option (right to buy)$23.33 (10)10/23/2029Common Stock0131,290D
Employee Stock Option (right to buy)$67.8512/19/202208/31/2030Common Stock64,95064,950(11)D
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $150.00 to $150.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. Represents the weighted average sales price per share. The shares sold at prices ranging from $151.00 to $151.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
4. Represents the weighted average sales price per share. The shares sold at prices ranging from $152.33 to $153.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
5. Represents the weighted average sales price per share. The shares sold at prices ranging from $153.34 to $154.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
6. Represents the weighted average sales price per share. The shares sold at prices ranging from $154.34 to $154.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
7. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
8. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
9. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
10. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
11. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust08/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR